Liminatus Pharma, Inc. Warrants

Liminatus Pharma, Inc. is a pre-clinical stage biopharmaceutical company focused on developing cancer therapies in the United States. Its lead candidate, IBA101, is a humanized anti-CD47 monoclonal antibody in Phase I clinical trials for advanced solid cancers, including non-small cell lung cancer. Founded in 2018, the company is based in Cerritos, California.